Liposomal bupivacaine is a formulation of local anesthetic which has the potential to provide anesthesia for up to 72 hours following administration. The purpose of this study was to compare the ...

Randomized trial of liposomal bupivacaine for hip fracture surgery Liposomal bupivacaine is a long-acting local anesthetic developed for use in relieving postoperative pain, allowing drug release ...

Randomized trial of liposomal bupivacaine for hip fracture surgery Liposomal bupivacaine is a long-acting local anesthetic ...

The company’s portfolio includes three commercially available products (liposomal bupivacaine, a cryoneurolysis device, and triamcinolone acetonide extended-release) as well as one gene therapy ...

Virpax announces positive results from minipig Dose Range Finding study for Probudur: Berwyn, Pennsylvania Monday, November 25, 2024, 18:00 Hrs [IST] Virpax Pharmaceuticals, Inc., ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

Virpax Pharmaceuticals (VRPX) announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company’s ...

Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose ...

Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to evaluate the ...

Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to evaluate the ...

Probudur is the company’s long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to ...